Technologieangebote

Ethynylated Heterodinucleotide Cytostatic Drugs for a better Cancer Therapy

Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.

Weitere Informationen: PDF

Eberhard Karls Universität Tübingen
Tel.: +49 (7071) 29-72639

Ansprechpartner
Dr. Rolf Hecker

Kommentare (0)

Schreiben Sie einen Kommentar